Good
Mostly Aligned
Patient Risk:
Low
Summary
The response correctly distinguishes prior anti-CMV treatment from prior systemic cancer therapy and accurately summarizes the labeled CMV indication. Its assertion that the supplied label identifies Takeda and therefore contradicts AstraZeneca is unsupported by the provided sections.
Category Scores
Accurate Statements
The label’s prior-treatment requirement does not establish a restriction based on prior systemic cancer therapy.
The indication is for post-transplant CMV infection or disease refractory to specified anti-CMV drugs; the supplied label does not address prior systemic cancer therapy.
The label indicates maribavir for refractory post-transplant CMV infection or disease.
Section 1 identifies LIVTENCITY as treatment for refractory post-transplant CMV infection or disease, and Section 11 identifies maribavir as its active ingredient.
Unsupported Statements
The label identifies Takeda as the company associated with the product, so AstraZeneca is contradicted by the label.
The supplied Section 16 gives tablet appearance and package sizes but does not identify Takeda, AstraZeneca, or a marketer. The provided sections cannot establish either company's association.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The unsupported company attribution does not alter the labeled indication, dose, or safety instructions. The response appropriately cautions against treating prior CMV therapy as equivalent to prior systemic cancer therapy.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Unsupported attribution of Takeda to the supplied label and the resulting claim that AstraZeneca is contradicted.
Suggested Improvement
Describe the marketer claim as not established by the supplied label sections; do not cite Section 16 as company information.